A Dose-proportionality Study of Five Tablet Strengths of ER OROS Paliperidone
Status:
Completed
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the dose proportionality of the 3-, 6-, 9-, 12-, and
15-mg tablets of ER OROS paliperidone. Additionally, the safety and tolerability of the
treatments in healthy volunteers will be assessed.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.